APDN
vs
S&P 500
APDN
S&P 500
Over the past 12 months, APDN has underperformed S&P 500, delivering a return of -98% compared to the S&P 500's +14% growth.
Stocks Performance
APDN vs S&P 500
Performance Gap
APDN vs S&P 500
Performance By Year
APDN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Applied DNA Sciences Inc
Glance View
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
